Revision of Precautions
Pazopanib hydrochloride

March 24, 2015

Non-proprietary name
Pazopanib hydrochloride

Safety measure
Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

Retinal detachment:
Retinal detachment may occur. Patients should be carefully monitored. If any abnormalities such as muscae volitantes, photopsia, visual field defect and reduced visual acuity are observed, ophthalmologic examination should be performed and appropriate measures such as discontinuation of administration should be taken.